Biotech dealmaking in the fall of 2002 was a study in crisis management. As cash-starved biotechs scrambled to avoid liquidation, they signed deals that kept them alive but hardly offered much hope for upside. The question they raise: when is it in shareholders' best interests to simply call it quits? "If you have to do Hail Mary passes at the last minute, you're risk of failure is high," explains Donald Hawthorne, CEO of BioTransplant Inc. which is itself trying to avoid a hasty, last-minute deal.
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
Many biotechs, facing crisis situations in the fall of 2002, opted for deals that kept them alive but hardly offered much hope for upside. But in the coming months, boards may need to be far more realistic about their long-term prospects and consider a full range of options, including liquidation, when assessing a company's future.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.